The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Panacea Biotec receives Rs. 315 crore LoA from UNICEF
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
India currently hosts more than 10,075 biotech startups
Subscribe To Our Newsletter & Stay Updated